Dimitrios Goumenos

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Hiddo J.L. Heerspink, Hans‐Henrik Parving, Dennis L. Andress et al. · The Lancet · 2019 · 612 citations · Full text

Medicine, Endocrinology, Nephrology +10

Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA

Alberto Ortíz, Mario Cozzolino, Danilo Fliser et al. · Nephrology Dialysis Transplantation · 2020 · 377 citations · Full text

Medicine, Nephrology, Dialysis +11

Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

Jonathan Barratt, Richard Lafayette, Jens Kristensen et al. · Kidney International · 2022 · 215 citations · Full text

Pharmacy, Nephrology, Pharmacotherapy +13

Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy

Krzysztof Kiryluk, Elena Sánchez, Francesca Zanoni et al. · Nature Genetics · 2023 · 172 citations · Full text

Life Sciences, Bioinformatics, Nephrology +17

Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update

Rosanna Coppo, Graziella D’Arrigo, Giovanni Tripepi et al. · Nephrology Dialysis Transplantation · 2018 · 111 citations · Full text

Medicine, Nephrology, Pathology +17